Anti-CD47 antibodies and methods of use
Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.
1. A method of treating cancer in a subject in need thereof, wherein the cancer comprises cells that express CD47, the method comprising administering to the subject an effective amount of an isolated anti-CD47 antibody molecule comprising a heavy chain complementarity determining region 1 (HC CDR1) of the amino acid sequence set forth in SEQ ID NO: 7, a heavy chain complementarity determining region 2 (HC CDR2) of the amino acid sequence set forth in SEQ ID NO: 8, a heavy chain complementarity determining region 3 (HC CDR3) of the amino acid sequence set forth in SEQ ID NO: 9, a light chain complementarity determining region 1 (LC CDR1) of the amino acid sequence set forth in SEQ ID NO: 10, a light chain complementarity determining region 2 (LC CDR2) of the amino acid sequence set forth in SEQ ID NO: 11, and a light chain complementarity determining region 3 (LC CDR3) of the amino acid sequence set forth in SEQ ID NO: 12.
2. The method of claim 1 , wherein the anti-CD47 antibody molecule is administered in combination with a chemotherapeutic agent or therapeutic antibody molecule.
3. The method of claim 1 , wherein the anti-CD47 antibody molecule is administered in combination with an opsonizing antibody molecule.
4. The method of claim 3 , wherein the opsonizing antibody molecule is an anti-CD19 antibody molecule, an anti-CD20 antibody molecule, or an anti-CD38 antibody molecule.
5. The method of claim 4 , wherein the opsonizing antibody molecule is an anti-CD20 antibody molecule.
6. The method of claim 4 , wherein the antibody molecule is rituximab.
7. The method of claim 1 , wherein the cancer i a hematological cancer.
8. The method of claim 7 , wherein the hematological cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), T-ALL, B-ALL, acute myelogenous leukemia (AML), Non-Hodgkin lymphoma, B-lymphoblastic leukemia/lymphoma; B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Burkitt's lymphoma, follicular lymphoma, SLL, marginal zone lymphoma, CNS lymphoma, Richter's Syndrome, multiple myeloma, myelofibrosis, polycythemia vera, cutaneous T-cell lymphoma, MGUS, myelodysplastic syndrome (MDS), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and anaplastic large cell lymphoma.
9. The method of claim 8 , wherein the hematological cancer is acute myelogenous leukemia (AML) or Burkitt's lymphoma.
10. The method of claim 1 , wherein the cancer is a solid tumor.
11. The method of claim 10 , wherein the cancer is a cancer of a tissue selected from the group consisting of: lung, pancreas, breast, liver, ovary, testicle, kidney, bladder, spine, brain, cervix, endometrium, colon/rectum, anus, esophagus, gallbladder, gastrointestinal tract, skin, prostate, pituitary, stomach, uterus, vagina, and thyroid.
12. The method of claim 1 , wherein the anti-CD47 antibody molecule comprises a heavy chain variable region (VH) of the amino acid sequence set forth in SEQ TD NO: 4 and a light chain variable region (VL) of the amino acid sequence set forth in SEQ ID NO: 6.
13. The method of claim 1 , wherein the anti-CD47 antibody molecule further comprises a wild type or mutant IgG1 heavy chain constant region.
14. The method of claim 1 , wherein the anti-CD47 antibody molecule further comprises a wild type or mutant IgG4 heavy chain constant region.
15. The method of claim 14 , wherein the IgG4 heavy chain constant region comprises one or both of the substitutions S228P and L235E.
16. The method of claim 1 , wherein the anti-CD47 antibody molecule comprises a heavy chain of the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25, and a light chain of the amino acid sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 26.
17. The method of claim 1 , wherein the anti-CD47 antibody molecule is administered in combination with a pharmaceutically acceptable carrier or diluent.
18. The method of claim 1 , wherein the anti-CD47 antibody molecule is administered subcutaneously.
19. The method of claim 1 , wherein the anti-CD47 antibody molecule is administered intravenously.
20. The method of claim 1 , wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, stomach cancer, colon cancer, prostate cancer, and uterine cancer.